Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up.

BACKGROUND The long-term outcome and spectrum of disease of nontuberculous mycobacterial immune reconstitution syndrome have not been described. METHODS We report the findings of an observational study. RESULTS Among 51 patients (43 with Mycobacterium avium complex [MAC] infection, 2 with Mycobacterium genavense infection, and 6 whose samples were smear positive but culture negative) from 1993-2004, the median follow-up period was 29 months. The incidence of nontuberculous mycobacterial immune reconstitution syndrome was 3.5% among patients initiating highly active antiretroviral therapy (HAART) with a baseline CD4+ cell count of <100 cells/microL. Three main clinical presentations were peripheral lymphadenitis (in 17 patients), pulmonary-thoracic disease (in 15 patients), and intra-abdominal disease (in 13 patients). Six other patients had cases that involved joint, spine, prostate, skin, soft tissue, and spontaneously resolving MAC bacteremia. Disease was usually localized. Median CD4+ cell counts before initiation of HAART and at diagnosis were 20 and 120 cells/microL, respectively, and the median reduction in human immunodeficiency virus (HIV) RNA load was 2.5 log10 copies/mL. Intra-abdominal disease was frequently preceded by disseminated MAC infection (in 62% of cases, compared with 6%-33% of cases for other groups; P=.003) and accounted for 16 (43%) of 36 hospitalizations (compared with 5%-35% for other groups; P=.008). The relapse rate was not higher among 10 patients who received no MAC therapy or received MAC therapy for < or =2 weeks. Prednisone was associated with clinical responses in 8 (89%) of 9 patients with evaluable cases. In total, 7 patients (14%) had 13 subsequent culture-positive MAC events (6 of which were cases of immune reconstitution syndrome, and 7 of which were cases of disseminated MAC infection). Ten patients (20%) died (2 of disseminated MAC infection, 5 of other opportunistic infections, and 3 of HIV-unrelated causes). CONCLUSIONS Nontuberculous mycobacterial immune reconstitution syndrome has a wide range of clinical presentations and severity. The long-term prognosis is favorable for HAART-adherent patients. Intra-abdominal disease is associated with greater morbidity than is peripheral lymphadenitis. The role of antimycobacterial therapy is uncertain, given the self-limited course of most nonabdominal cases.

[1]  S. Shelburne,et al.  The immune reconstitution inflammatory syndrome. , 2003, AIDS reviews.

[2]  B. Coldiron,et al.  Mycobacterium avium-Mycobacterium intracellulare infection limited to the skin and lymph nodes in patients with AIDS. , 1989, Reviews of infectious diseases.

[3]  C. Horsburgh.  Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. , 1991, The New England journal of medicine.

[4]  D. Havlir,et al.  Effect of potent antiretroviral therapy on immune responses to Mycobacterium avium in human immunodeficiency virus-infected subjects. , 2000, The Journal of infectious diseases.

[5]  E. Graviss,et al.  Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy , 2005, AIDS.

[6]  J. Currier,et al.  A phase II/III trial of antimicrobial therapy with or without amikacin in the treatment of disseminated Mycobacterium avium infection in HIV‐infected individuals , 1998, AIDS.

[7]  P. Sax,et al.  Recurrence of Mycobacterium avium infection in patients receiving highly active antiretroviral therapy and antimycobacterial agents. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  M. Policar,et al.  Isolated pulmonary Mycobacterium avium complex infection in patients with human immunodeficiency virus infection: case reports and literature review. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  J. Singer,et al.  A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. , 1996, The New England journal of medicine.

[10]  P. Reiss,et al.  Patterns of T-cell repopulation, virus load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[11]  Evan Wood,et al.  Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy? , 2003, AIDS.

[12]  S. Mallal,et al.  Zidovudine‐induced restoration of cell‐mediated immunity to mycobacteria in immunodeficient HIV‐infected patients , 1992, AIDS.

[13]  D. Musher,et al.  Immune Reconstitution Inflammatory Syndrome: Emergence of a Unique Syndrome During Highly Active Antiretroviral Therapy , 2002, Medicine.

[14]  Julio S. G. Montaner,et al.  Azithromycin prophylaxis for Mycobacterium avium complex during the era of highly active antiretroviral therapy: evaluation of a provincial program. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  C. Horsburgh,et al.  A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  Prabhat Kumar Sharma,et al.  Reactional states and neuritis in multibacillary leprosy patients following MDT with/without immunotherapy with Mycobacterium w antileprosy vaccine. , 2000, Leprosy review.

[17]  Julio S. G. Montaner,et al.  Effect of Medication Adherence on Survival of HIV-Infected Adults Who Start Highly Active Antiretroviral Therapy When the CD4+ Cell Count Is 0.200 to 0.350 109 cells/L , 2003, Annals of Internal Medicine.

[18]  R. Chaisson,et al.  Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic: Mycobacterium avium complex disease in patients with HIV infection , 1997, AIDS.

[19]  W. Chan,et al.  Immunorestitution disease involving the innate and adaptive response. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  M. Lederman,et al.  Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy. , 2000, The Journal of infectious diseases.

[21]  Julio S. G. Montaner,et al.  Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. , 2001, JAMA.

[22]  J Leibowitch,et al.  Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. , 1997, Science.

[23]  J. Lieberman,et al.  Paradoxical enlargement or development of intracranial tuberculomas during therapy: case report and review. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  E. Bergot,et al.  Acute respiratory failure following HAART introduction in patients treated for Pneumocystis carinii pneumonia. , 2001, American journal of respiratory and critical care medicine.

[25]  Horsburgh Cr.  Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. , 1991, The New England journal of medicine.

[26]  P. Price,et al.  Immune restoration disease after antiretroviral therapy , 2004, AIDS.

[27]  R. Pomerantz,et al.  Inflammatory Reactions in HIV-1Infected Persons after Initiation of Highly Active Antiretroviral Therapy , 2000, Annals of Internal Medicine.

[28]  P. Phillips.  Immunoresititution disease in relation to infection with Mycobacterium avium complex and to leprosy. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  R. Pomerantz,et al.  Treatment of Mycobacterium avium complex immune reconstitution disease in HIV-1-infected individuals. , 2003, AIDS patient care and STDs.

[30]  J. Grosset,et al.  Clarithromycin resistance and susceptibility patterns of Mycobacterium avium strains isolated during prophylaxis for disseminated infection in patients with AIDS. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  N. Letvin,et al.  Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease , 1998, The Lancet.

[32]  J. Currier,et al.  Localized osteomyelitis due to Mycobacterium avium complex in patients with Human Immunodeficiency Virus receiving highly active antiretroviral therapy. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  J. Williams,et al.  Mycobacterium avium complex infection presenting as endobronchial lesions in immunosuppressed patients. , 1988, Annals of internal medicine.

[34]  M. John,et al.  Immune restoration disease after the treatment of immunodeficient HIV‐infected patients with highly active antiretroviral therapy , 2000, HIV medicine.

[35]  S. Lawn,et al.  Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. , 2005, The Lancet. Infectious diseases.

[36]  J. Montaner,et al.  Mycobacterial lymphadenitis associated with the initiation of combination antiretroviral therapy. , 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.